目的探讨鞘内注射甲基强的松龙治疗急性期多发性硬化患者的临床疗效。方法选取2015年7月至2016年10月在辽宁省北票市中医院治疗的急性期多发性硬化患者92例,随机分为对照组与观察组,各46例。对照组患者给予甲基强的松龙冲击治疗,观察组患者行甲基强的松龙鞘内注射治疗,比较两组患者的临床疗效。结果两组患者治疗后2周外周血CD8~+、CD4~+/CD8~+及脑脊液CD4~+、CD8~+均明显优于治疗前,差异均有统计学意义(均P<0.05);治疗后2周,观察组患者Kurtzke扩展致残量表(EDSS)评分明显低于对照组,差异有统计学意义(P<0.05);观察组患者住院时间明显短于对照组,住院费用明显少于对照组,差异均有统计学意义(均P<0.05)。结论鞘内注射甲基强的松龙治疗急性期多发性硬化起效较快,可促使患者神经功能改善,对T淋巴细胞亚群平衡予以调节。 Objective To investigate the clinical efficacy of intrathecal methylprednisolone in the treatment of acute multiple sclerosis. Methods From July 2015 to October 2016, 92 patients with acute multiple sclerosis treated in Beipiao Hospital of Traditional Chinese Medicine in Liaoning Province were randomly divided into control group and observation group, with 46 cases in each group. Patients in the control group were given methylprednisolone impact therapy. Patients in the observation group were treated with methylprednisolone intrathecal injection, and the clinical efficacy was compared between the two groups. Results The levels of CD8 ~ +, CD4 ~ + / CD8 ~ + in peripheral blood and CD4 ~ + and CD8 ~ + in cerebrospinal fluid in two groups after treatment were significantly better than those before treatment (all P <0.05). Two weeks after treatment, the Kurtzke EDSS scores in the observation group were significantly lower than those in the control group (P <0.05). The hospitalization time in the observation group was significantly shorter than that in the control group, and the hospitalization cost was significantly lower In the control group, the differences were statistically significant (all P <0.05). Conclusion Intrathecal methylprednisolone treatment of multiple sclerosis acute onset of rapid onset, can promote the improvement of neurological function in patients with T lymphocyte subsets to be balanced.